LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Hemoglobin (Hb) A1c With GlycoMark® Reflex

CPT: 83036; 84378
Updated on 01/29/2020
Print Share


  • Hb A1c With GlycoMark® Reflex

Test Includes

Estimated average glucose (eAG); GlycoMark® (1,5 AG) reflex; hemoglobin A1c

Estimated average glucose (eAG); GlycoMark® (1,5 AG) reflex; hemoglobin A1c

Expected Turnaround Time

3 - 10 days

Specimen Requirements


Serum or plasma and whole blood, refrigerated


1 mL serum or plasma and 3 mL whole blood

Minimum Volume

0.75 mL serum or plasma and 1 mL whole blood (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube or EDTA plasma tube and lavender-top (EDTA) tube or green top (litium heparin) tube or gray top (sodium fluoride) tube


Separate serum or plasma from cells within one hour of collection. Ship in plastic transport tube.

Storage Instructions

Refrigerate serum or plasma and whole blood

Stability Requirements

Serum or Plasma




14 days


14 days

Freeze/thaw cycles

Stable x6

Whole blood



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Test Details


GlycoMark® testing provides an estimate of the patient's postmeal glucose over a one- to two-week period, making it ideal for intermediate term monitoring of glycemic control in diabetic patients. GlycoMark® testing can also help monitor the effectiveness of therapeutics targeting postprandial glucose (PPG),1,2 and it is a useful adjunct to routine A1c testing because it responds more rapidly and sensitively to hyperglycemia than A1c.1,2

Hb A1c testing provides an estimate of the patient's average blood glucose over a period of two to three months. Hb A1c testing helps assess the long term diabetic control for individuals with diabetes mellitus.


Individuals using INVOKANA® may demonstrate low levels of 1,5-AG. 1,5-AG blood levels are falsely lowered by the diabetes drug INVOKANA® which prevents reabsorption of 1,5-AG in the kidneys. INVOKANA® belongs to new class of diabetes medication known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which block reabsorption of glucose in the kidneys, and other SGLT2 inhibitors may have the same effect. INVOKANA® is a trademark of Janssen Pharmaceuticals Inc.

Persistently positive urinary glucose levels, or oxyhyperglycemia after gastrectomy, may result in a low 1,5-AG value. Low values have also been observed in pregnancy, terminal stage renal failure, dialysis patients, advanced cirrhosis, and prolonged incapability of oral ingestion of food. Abnormal values have also been noted in individuals with abnormal glomerular filtration rates.3,4

For some patients with severe hyperglycemia, the internal pool of 1,5-AG may tend to remain depleted as a result of persistent glucosuria. In these cases, measurements of 1,5-AG may be less indicative of initial recovery following initiation of antidiabetic treatment.

1,5-AG values may be increased when some Chinese medicines, such as Polygala Tenuifolia and Senega syrup, are administered. Values may also be increased during intravenous hyperalimentation. 1,5-AG values may be lower in patients undergoing therapy with steroids.5

Some alpha-glucosidase inhibitors, such as Acarbose, may potentially reduce 1,5-AG levels due to interference with intestinal absorption of 1,5-AG.

As with all diagnostic tests, GlycoMark® results should be interpreted along with clinical findings and results from other diagnostic methods.


See individual assays. GlycoMark® is a registered trademark of GlycoMark Inc, New York, NY.

Reference Interval

Note: The patient's date of birth (DOB) and/or gender was not provided. Consequently, a complete set of reference range data are shown. When DOB and/or gender is provided, only the appropriate age/gender reference range is printed.

GlycoMark® (1,5 AG)

0-17 years

Range not established

Adult male

10.7-32.0 μg/mL

Adult female

6.8-29.3 μg/mL

Glycemic control goal for diabetic patients: >10

GlycoMark® is intended for managing glycemic control in diabetic patients. A low result corresponds to high glucose peaks.

Normal: <5.7

Hemoglobin A1c

Increased risk for diabetes: 5.7-6.4

Ongoing hyperglycemia: >6.4

Estimated average glucose

Glycemic control for adults with diabetes: <7.0 (ADA)

Note: A reflex test was ordered on this specimen. If A1c results are between 6.0 and 8.0 (including 6.0 and 8.0), GlycoMark testing is performed. GlycoMark reflects postprandial glucose spikes from the previous two weeks, whereas A1c reflects average glycemic control during the previous three months.

Additional Information

1,5 Anhydroglucitol (1,5-AG) is a naturally occurring monosaccharide found in nearly all foods. Individuals without diabetes and those with diabetes but have well-controlled blood glucose levels <180 mg/dL have detectably high levels of 1,5-AG. When a individual's glucose levels are in a normal range, 1,5-AG is naturally processed by the kidneys and nearly all of it is reabsorbed back into the blood stream by the renal proximal tubules. Individuals with diabetes that have blood glucose level excursion in excess >180 mg/dL can be expected to have low levels of 1,5-AG. In these individuals, excess glucose in the body is reabsorbed first by the kidneys, blocking 1,5-AG reabsorption. The body is unable to maintain a high steady state level of 1,5-AG in blood and tissues.

• Normal or high GlycoMark® values = Normal blood glucose levels

• Low GlycoMark® values = Elevated blood glucose levels or high blood glucose spikes

• Normal levels of glucose produce a normal amount of Hb A1c. As the average amount of plasma glucose increases, the fraction of Hb A1c increases in a predictable way. This test serves as an indicator for average blood glucose levels over the previous two to three months prior to the measurement.

• Normal Hb A1c values = Normal blood glucose

• Higher Hb A1c values = Elevated blood glucose levels


1. Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006 Jun; 29(6):1214-1219. 16731998
2. Dworacka M, Winiarska H, Szymanska M, et al. 1,5-Anhydro-D-glucitol: A novel marker of glucose excursions. Int J Clin Pract Suppl. 2002 Jul; (129):40-44. 12166605
3.Yamanuchi S. Guide for Laboratory Tests. 1992: 597-599.
4. Minoda S. Influence of long-term total nutrition on l,5-anhydroglucitol in the human body. Teikyo Medical J. 1993; 6(4):321-333.
5. Kato C, Morishita Y, Fukatsu T. [False-positive increase in 1,5-anhydro-D-glucitol due to Kampo (Japanese herbal) medicine.]Rinsho Byori. 1996 Apr; 44(4):396-399. (Article in Japanese) 8847825


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
503205 A1c w/GlycoMark(R) Reflex 502359 Hb A1c Diabetic Assessment %Hb 4548-4
503205 A1c w/GlycoMark(R) Reflex 503208 Estimated Average Glucose mg/dL 27353-2
503205 A1c w/GlycoMark(R) Reflex 500117 GlycoMark(R)(1,5 AG) ug/mL 53835-5

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at